Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral tacrolimus pilot study in hereditary hemorrhagic telangiectasia
2019-003585-40Phase 2Active
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Sep 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in hereditary hemorrhagic telangiectasia (HHT), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Change in hemoglobin. Started Sep 2019; status: active.
02
Drugs
tacrolimus
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on 2019-003585-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003585-40.